Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and Methods for Modulating Inflammation Using Fluoroquinolones

Inactive Publication Date: 2008-12-11
BAUSCH & LOMB INC
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017]In still another aspect, the present invention provides a method for modulating an inflammation in a subject. The method comprises administering into the subject an effective amount of the fluoroquinolone having Formula I or a salt thereof to modulate the inflammation.
[0018]In yet another as

Problems solved by technology

The interface between the body and its environment is large, and thus presents many potential opportunities for invasion by environmental virulent pathogens.
The outer tissues of the eye constitute parts of this interface, and thus, the eye and its surrounding tissues are also vulnerable to virulent microorganisms, the invasion and uncontrolled growth of which cause various types of ophthalmic infections, such as blepharitis, conjunctivitis, keratitis, or trachoma, which can result in serious impairment of vision if untreated.
Ocular or ophthalmic infections can cause severe pain, swollen and red tissues in or around the eye, and blurred and decreased vision.
Although an inflammatory response is essential to clear pathogens from the site of infection, a prolonged or overactive inflammatory response can be damaging to the surrounding tissues.
As a result, these dilated vessels become leaky.
However, steroidal drugs can have side effects that threaten the overall health of the patient.
It is also known that the risk of IOP elevations associated with the topical ophthalmic use of glucocorticoids increases over time.
In other words, the chronic (i.e., long-term) use of these agents increases the risk of significant IOP elevations.
This chronic use of corticosteroids significantly increases the risk of IOP elevations.
In addition, use of corticosteroids is also known to increase the risk of cataract formation in a dose- and duration-dependent manner.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and Methods for Modulating Inflammation Using Fluoroquinolones
  • Compositions and Methods for Modulating Inflammation Using Fluoroquinolones
  • Compositions and Methods for Modulating Inflammation Using Fluoroquinolones

Examples

Experimental program
Comparison scheme
Effect test

example 1

Solution

[0088]

IngredientAmount (% by weight)Compound having Formula IV0.2Hydroxypropylmethylcellulose (“HPMC”)0.5Benzakonium chloride (“BAK”)0.01Pluronic ® F1270.1EDTA0.1NaCl0.25Phosphate buffer (0.05M, pH = 5.0)q.s. to 100

[0089]An appropriate proportion (shown in the above table) of Pluronic® F127 is added to phosphate buffer in a sterilized stainless steel jacketed vessel equipped with a stirring mechanism, at a temperature in the range from 50 to 60° C. The resulting buffer solution is heated to 61 to 75° C. At a temperature of about 66° C., an appropriate amount of BAK is added to the buffer solution while mixing three to ten minutes. At a temperature of 75° C., an appropriate amount of the compound having Formula IV is added to the contents of the vessel over a period of three to five minutes while mixing continues. EDTA and NaCl are then added to the mixture while mixing continues for five more minutes at 75° C. The resulting mixture is cooled to 25 to 30° C. The final composi...

example 2

Solution

[0090]A procedure similar to that of Example 1 is used to produce this solution.

IngredientAmount (% by weight)Compound having Formula IV0.35Mannitol4.5Benzakonium chloride (“BAK”)0.005Polysorbate 800.1EDTA0.05Sodium acetate0.03Acetic acid0.04Purified waterq.s. to 100

example 3

Solution

[0091]A procedure similar to that of Example 1 is used to produce this solution having the following composition.

IngredientAmount (% by weight)Compound having Formula IV0.2Dexamethasone0.1Hydroxypropylmethyl cellulose (“HPMC”)0.5Alexidine0.01Brij ® surfactant0.1EDTA0.1Citrate buffer (0.02M sodium citrate, pH = 5.0)q.s. to 100

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Percent by massaaaaaaaaaa
Weightaaaaaaaaaa
Login to View More

Abstract

Compositions for modulating an inflammation comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating an inflammation comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating an ocular or ophthalmic inflammation, including uveitis, vernal keratoconjunctivitis, or inflammation associated with contact lens-associated corneal infiltrates.

Description

CROSS REFERENCE[0001]This application claims the benefit of Provisional Patent Application No. 60 / 943,154 filed Jun. 11, 2007 which is incorporated by reference herein.BACKGROUND OF THE INVENTION[0002]The present invention relates to compositions and methods for modulating inflammation using fluoroquinolones. In particular, the present invention relates to compositions and methods for modulating ocular or ophthalmic inflammation using fluoroquinolones. In addition, the present invention relates to compositions and methods for treating, controlling, reducing, or ameliorating ocular or ophthalmic infections and their resulting inflammation using fluoroquinolones.[0003]The interface between the body and its environment is large, and thus presents many potential opportunities for invasion by environmental virulent pathogens. The outer tissues of the eye constitute parts of this interface, and thus, the eye and its surrounding tissues are also vulnerable to virulent microorganisms, the i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61K31/55A61K31/551A61P27/02A61K31/573
CPCA61K31/55A61K31/58A61K31/573A61K31/551A61P27/02A61P29/00A61P31/00A61P43/00A61K31/553A61K31/554
Inventor ZHANG, JINZHONGWARD, KEITH WAYNE
Owner BAUSCH & LOMB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com